CRNX Crinetics Pharmaceuticals Inc
Price (delayed)
$31.39
Market cap
$2.92B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.69
Enterprise value
$2.71B
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate,
Highlights
CRNX's equity has surged by 146% year-on-year and by 59% since the previous quarter
The quick ratio has soared by 79% YoY and by 41% QoQ
The revenue has dropped by 74% year-on-year
CRNX's gross profit has plunged by 74% YoY
Key stats
What are the main financial stats of CRNX
Market
Valuations
Earnings
Shares outstanding
93.05M
Market cap
$2.92B
Enterprise value
$2.71B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.2
Price to sales (P/S)
2,440.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,605.84
Revenue
$1.04M
Gross profit
$1.04M
Operating income
-$338.85M
Net income
-$298.41M
EBIT
-$298.41M
EBITDA
-$292.58M
Free cash flow
-$229.81M
Per share
Balance sheet
Liquidity
EPS
-$3.69
EPS diluted
-$3.69
Free cash flow per share
-$2.84
Book value per share
$14.29
Revenue per share
$0.01
TBVPS
$17.76
Total assets
$1.43B
Total liabilities
$109.79M
Debt
$51.72M
Equity
$1.32B
Working capital
$1.32B
Debt to equity
0.04
Current ratio
23.04
Quick ratio
22.7
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
-28,159.9%
Gross margin
100%
Net margin
-28,720.7%
Operating margin
-32,613.5%
Return on assets
-27.9%
Return on equity
-30.9%
Return on invested capital
-39.9%
Return on capital employed
-21.7%
Return on sales
-28,720.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRNX stock price
How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
2.51%
1 week
-9.04%
1 month
-12.27%
1 year
-31.76%
YTD
-38.61%
QTD
-6.41%
Financial performance
How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$1.04M
Gross profit
$1.04M
Operating income
-$338.85M
Net income
-$298.41M
Gross margin
100%
Net margin
-28,720.7%
The revenue has dropped by 74% year-on-year
CRNX's gross profit has plunged by 74% YoY
CRNX's operating income has plunged by 52% YoY and by 10% from the previous quarter
CRNX's net income is down by 39% year-on-year and by 7% since the previous quarter
Growth
What is Crinetics Pharmaceuticals's growth rate over time
Valuation
What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.2
P/S
2,440.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,605.84
CRNX's equity has surged by 146% year-on-year and by 59% since the previous quarter
CRNX's P/B is 48% below its last 4 quarters average of 4.1 and 39% below its 5-year quarterly average of 3.5
The revenue has dropped by 74% year-on-year
The P/S is 63% above the 5-year quarterly average of 1457.5 but 22% below the last 4 quarters average of 3045.9
Efficiency
How efficient is Crinetics Pharmaceuticals business performance
The company's return on equity rose by 42% YoY and by 14% QoQ
The ROA has increased by 39% YoY and by 13% from the previous quarter
The return on invested capital rose by 27% year-on-year and by 13% since the previous quarter
The company's return on sales fell by 7% QoQ
Dividends
What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRNX.
Financial health
How did Crinetics Pharmaceuticals financials performed over time
The total assets has surged by 126% year-on-year and by 53% since the previous quarter
The quick ratio has soared by 79% YoY and by 41% QoQ
The debt is 96% smaller than the equity
CRNX's equity has surged by 146% year-on-year and by 59% since the previous quarter
CRNX's debt to equity has dropped by 60% year-on-year and by 33% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.